The Jackson Clinic, PA

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer3 trials
• Heart failure3 trials
• Familial hypercholesterolaemia2 trials
• Multiple myeloma2 trials
• Obesity2 trials
• Atrial fibrillation1 trial
• COPD1 trial
• Coronary artery disease1 trial
• Diabetic foot ulcer1 trial
• Lung cancer1 trial

Phase

• Phase 37 trials
• Phase 41 trial

Status

• Recruiting6 trials
• Active, not recruiting4 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Freenome Holdings Inc.2 trials
• National Cancer Institute (NCI)2 trials
• Amgen1 trial
• Duke University1 trial
• Energenesis Biomedical Co., Ltd.1 trial
• and 6 more

Running trials

• Recruiting

  ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

  NCT06716021· Phase 3· Milestone Pharmaceuticals Inc.· Source

  Contact: Lindsay Jones

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  NCT06909565· Phase 4· Duke University· Source

  Contact: Felecia Bruton

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

  NCT06122077· Freenome Holdings Inc.· Source

  Contact: Study Coordinator

• Recruiting

  A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

  NCT05930210· Phase 3· Energenesis Biomedical Co., Ltd.· Source

  Contact: Kellie Wallace-Wilding, Dr.

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

  NCT04136002· Guardant Health, Inc.· Source

• Active, not recruiting

  Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

  NCT00644228· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT00602641· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure2 recruiting
• Obesity2 recruiting
• Atrial fibrillation1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Diabetic foot ulcer1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Lung cancer1 recruiting

Closed trials

• Terminated

  Informed Choice - Compass

  NCT05246839· Exact Sciences Corporation· Source

• Completed

  Prevention of Colorectal Cancer Through Multiomics Blood Testing

  NCT04369053· Freenome Holdings Inc.· Source

• Completed

  Benefits of µCor in Ambulatory Decompensated Heart Failure

  NCT03476187· Zoll Medical Corporation· Source